Josh Schimmer
Stock Analyst at Evercore ISI Group
(3.42)
# 978
Out of 4,753 analysts
119
Total ratings
41.35%
Success rate
6.39%
Average return
Main Sectors:
Stocks Rated by Josh Schimmer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SPRO Spero Therapeutics | Downgrades: In-Line | $5 | $0.88 | +470.13% | 4 | Dec 20, 2024 | |
| JANX Janux Therapeutics | Reiterates: Overweight | $200 | $44.65 | +347.93% | 6 | Dec 11, 2024 | |
| TRML Tourmaline Bio | Reiterates: Overweight | $25 | $15.98 | +56.45% | 1 | Dec 11, 2024 | |
| ZURA Zura Bio | Reiterates: Overweight | n/a | $1.78 | - | 5 | Dec 11, 2024 | |
| RCKT Rocket Pharmaceuticals | Reiterates: Overweight | $65 | $11.24 | +478.29% | 4 | Nov 19, 2024 | |
| SEPN Septerna | Initiates: Overweight | $50 | $14.39 | +247.46% | 1 | Nov 19, 2024 | |
| SPRY ARS Pharmaceuticals | Reiterates: Overweight | $30 | $12.75 | +135.29% | 4 | Oct 8, 2024 | |
| FDMT 4D Molecular Therapeutics | Downgrades: Neutral | n/a | $6.14 | - | 3 | Sep 23, 2024 | |
| ALEC Alector | Reiterates: Overweight | n/a | $1.84 | - | 2 | Sep 17, 2024 | |
| ASND Ascendis Pharma | Maintains: Outperform | $191 → $205 | $129.41 | +58.41% | 1 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $90 | $39.30 | +129.01% | 6 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $70 | $33.54 | +108.71% | 9 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $6.84 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $81.45 | - | 5 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $20.27 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $17.93 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $3.70 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $68.56 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $162.44 | - | 4 | Aug 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 | $0.88 | +1,606.68% | 3 | Aug 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $53 | $34.68 | +52.83% | 5 | Aug 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $23 | $4.88 | +371.31% | 1 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $65 | $40.15 | +61.89% | 3 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $60 | $52.28 | +14.77% | 5 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $2.44 | +1,949.18% | 1 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $75 | $30.32 | +147.36% | 3 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $43 → $5 | $1.85 | +170.27% | 2 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $11 | $1.83 | +501.09% | 2 | Jun 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $140 → $130 | $151.20 | -14.02% | 1 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $760 | $716.72 | +6.04% | 2 | Oct 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $15 | $14.95 | +0.33% | 1 | Mar 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $55 | $10.30 | +433.98% | 1 | Feb 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $1.79 | +1,575.98% | 1 | Dec 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $2.50 | - | 4 | Dec 9, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $8.43 | - | 3 | Feb 25, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $222 → $250 | $339.97 | -26.46% | 4 | Nov 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $3,500 → $4,600 | $6.96 | +65,991.95% | 4 | Jun 19, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $75.26 | - | 2 | Jun 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $33.17 | - | 2 | May 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $5.66 | - | 2 | Mar 12, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $23.59 | - | 2 | Mar 12, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $16.13 | +36.39% | 1 | Nov 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $9.72 | - | 2 | Aug 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $64.19 | - | 1 | Aug 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $95 | $191.75 | -50.46% | 1 | Aug 17, 2017 |
Spero Therapeutics
Dec 20, 2024
Downgrades: In-Line
Price Target: $5
Current: $0.88
Upside: +470.13%
Janux Therapeutics
Dec 11, 2024
Reiterates: Overweight
Price Target: $200
Current: $44.65
Upside: +347.93%
Tourmaline Bio
Dec 11, 2024
Reiterates: Overweight
Price Target: $25
Current: $15.98
Upside: +56.45%
Zura Bio
Dec 11, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.78
Upside: -
Rocket Pharmaceuticals
Nov 19, 2024
Reiterates: Overweight
Price Target: $65
Current: $11.24
Upside: +478.29%
Septerna
Nov 19, 2024
Initiates: Overweight
Price Target: $50
Current: $14.39
Upside: +247.46%
ARS Pharmaceuticals
Oct 8, 2024
Reiterates: Overweight
Price Target: $30
Current: $12.75
Upside: +135.29%
4D Molecular Therapeutics
Sep 23, 2024
Downgrades: Neutral
Price Target: n/a
Current: $6.14
Upside: -
Alector
Sep 17, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.84
Upside: -
Ascendis Pharma
Sep 17, 2024
Maintains: Outperform
Price Target: $191 → $205
Current: $129.41
Upside: +58.41%
Sep 16, 2024
Reiterates: Overweight
Price Target: $90
Current: $39.30
Upside: +129.01%
Sep 16, 2024
Reiterates: Overweight
Price Target: $70
Current: $33.54
Upside: +108.71%
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $6.84
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $81.45
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $20.27
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $17.93
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $3.70
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $68.56
Upside: -
Aug 29, 2024
Reiterates: Overweight
Price Target: n/a
Current: $162.44
Upside: -
Aug 26, 2024
Maintains: Outperform
Price Target: $15
Current: $0.88
Upside: +1,606.68%
Aug 26, 2024
Maintains: Outperform
Price Target: $54 → $53
Current: $34.68
Upside: +52.83%
Aug 13, 2024
Initiates: Overweight
Price Target: $23
Current: $4.88
Upside: +371.31%
Aug 9, 2024
Reiterates: Overweight
Price Target: $65
Current: $40.15
Upside: +61.89%
Aug 8, 2024
Maintains: Overweight
Price Target: $50 → $60
Current: $52.28
Upside: +14.77%
Jun 21, 2024
Reiterates: Overweight
Price Target: $50
Current: $2.44
Upside: +1,949.18%
May 6, 2024
Reiterates: Overweight
Price Target: $75
Current: $30.32
Upside: +147.36%
Nov 10, 2023
Downgrades: In-Line
Price Target: $43 → $5
Current: $1.85
Upside: +170.27%
Jun 6, 2023
Maintains: Outperform
Price Target: $20 → $11
Current: $1.83
Upside: +501.09%
Nov 14, 2022
Downgrades: In-Line
Price Target: $140 → $130
Current: $151.20
Upside: -14.02%
Oct 17, 2022
Downgrades: In-Line
Price Target: $760
Current: $716.72
Upside: +6.04%
Mar 15, 2022
Initiates: Outperform
Price Target: $15
Current: $14.95
Upside: +0.33%
Feb 2, 2021
Initiates: Outperform
Price Target: $55
Current: $10.30
Upside: +433.98%
Dec 29, 2020
Initiates: Outperform
Price Target: $30
Current: $1.79
Upside: +1,575.98%
Dec 9, 2019
Downgrades: In-Line
Price Target: n/a
Current: $2.50
Upside: -
Feb 25, 2019
Upgrades: Outperform
Price Target: n/a
Current: $8.43
Upside: -
Nov 16, 2018
Upgrades: Outperform
Price Target: $222 → $250
Current: $339.97
Upside: -26.46%
Jun 19, 2018
Upgrades: Outperform
Price Target: $3,500 → $4,600
Current: $6.96
Upside: +65,991.95%
Jun 11, 2018
Upgrades: Outperform
Price Target: n/a
Current: $75.26
Upside: -
May 8, 2018
Downgrades: In-Line
Price Target: n/a
Current: $33.17
Upside: -
Mar 12, 2018
Downgrades: In-Line
Price Target: n/a
Current: $5.66
Upside: -
Mar 12, 2018
Downgrades: In-Line
Price Target: n/a
Current: $23.59
Upside: -
Nov 7, 2017
Initiates: Outperform
Price Target: $22
Current: $16.13
Upside: +36.39%
Aug 17, 2017
Initiates: Outperform
Price Target: n/a
Current: $9.72
Upside: -
Aug 17, 2017
Initiates: Outperform
Price Target: n/a
Current: $64.19
Upside: -
Aug 17, 2017
Initiates: Outperform
Price Target: $95
Current: $191.75
Upside: -50.46%